BGI Genomics released the 2022 annual fiscal forecast. The operating revenue is expected to reach CNY 6.4 to 7.4 billion; the net profit attributable to shareholders of the listed companies is forecast to be CNY 800 million to 1.04 billion.

Continued improvement in the competitiveness of regular business and sufficient momentum of long-term development

During the reporting period, BGI increased the ratio of R & D investment in operating revenue compared with that of the previous year. High investment in R & D has yielded results that a number of products being approved for market launch and the product layout further broadened to continuously meeting market demand —— CNV-seq, entirely automated PCR analysis system PMEasyLab and its supporting multiplex nucleic acid test kit for pathogens of central nervous system infections, multiplex testing for bacterial drug resistance genes and monkeypox virus test kit have all received CE Mark.

GBIMToF-1000 time-of-flight mass spectrometry detection system, alpha and beta thalassaemia gene detection kit and chromosome aneuploidy detection products have all obtained NMPA certificates.

Meanwhile, BGI further expands its influence in fertility health and tumor prevention and control. During the reporting period, BGI upgraded Angel Care newborn and child genetic detection, WGS, EmbrySeq PGT-M, leukaemia genetic detection series, PMseq high-throughput genetic detection for pathogenic microorganisms and monogenic genetic diseases carrier screening, released the hundred-yuan class non-invasive liver cancer genetic detection, and newly launched COLOTECT v3.0 non-invasive bowel cancer DNA methylation and hemoglobin combination detection.

In addition, to further improve the efficiency of bioinformatics business analysis and processing, during the reporting period, BGI released the LUSH gene sequence alignment accelerated tool set and the one-stop data management service system for birth defect prevention and control, comprehensively upgraded the all-in-one gene analysis machine HALOS and the gene cloud computing platform GeneAn, unveiled the newborn disease screening management system, and newly launched the Dr.Tom macro genetic data delivery system to manage relevant data.

In terms of new business development, BGI launched a number of tandem mass spectrometry-based assays for various cardiovascular and cerebrovascular diseases, helping the prevention and early intervention of chronic diseases through precision testing technology.

Continued internationalization strategy and accelerated expansion in overseas markets

In 2022, BGI continued to promote the development of regular business and the transformation of overseas business. During the reporting period, to support the leading role in global market layout, BGI continued strategic deployment to expand its sales market and strengthen overseas sales force.

During the reporting period, relied on the overseas channel advantage of Fire Eye Lab, BGI accelerated the conversion scale of regular business, and actively laid out a number of overseas independent medical laboratories (ICL) to constantly strengthen international cooperation and technology conversion; in addition, BGI leveraged its technical advantages and engineering capabilities to implement the "front shop and back factory" strategic plan and continued to promote the high-quality operation of Ethiopia IVD factories.

BGI stated that, with its platform advantages and brand value, the company will accelerate the product introduction towards overseas markets such as fertility health, tumor prevention and control, infection prevention and control, and further expand overseas business and global influence, thereby increasing the level of profit contribution in the international market and providing important support for the company's steady growth and sustainable development, with a view to further enhancing its future growth.